Cancer Metabolism Hub

The BCI Cancer Metabolism Hub brings together research groups exploring how metabolism changes in cancer, and how these insights can be translated into improved clinical care.

The BCI Cancer Metabolism Hub is a community of research groups that are investigating the fundamental metabolic alterations that take place in human cancers, translating these novel discoveries into clinical advances. The work performed by this group encompasses the whole range of translational research from understanding the basic science of cancer metabolism, through to leading advanced phase clinical trials of novel anti-metabolic therapies in cancer patients.

Why study cancer metabolism?

Almost 100 years ago, Otto Warburg discovered that cancer cells exhibit an altered metabolism: switching from oxidative phosphorylation to aerobic glycolysis (now termed the Warburg effect). Although quiet for many years, the field of cancer metabolism has experienced a revolution in the last decade. It is now recognized as one of the hallmarks of cancer, and metabolism research is rapidly evolving and expanding to unveil new pathways and molecular mechanisms beyond the Warburg effect: for example, changes in the metabolism of sugars, lipids, amino acids and other sources of energy. As a result, new therapeutic approaches targeting cellular metabolism are being tested with varied success in different cancer types, expanding the range of current treatment options.  

Meet the hub members

Dr Katiuscia Bianchi

Reader in Cell Biology

Professor Andy Finch

Professor of Cancer Metabolism

Dr Paolo Gallipoli

Clinical Reader in Experimental Haematology

Professor Kairbaan Hodivala-Dilke

Professor of the Tumour Microenvironment

Dr Barrie Peck

Senior Lecturer

Dr John Riches

Clinical Reader in Cancer Immuno-metabolism

Dr Kevin Rouault-Pierre

Reader in Stem Cell Biology and Disease

Professor Tyson V. Sharp

Professor of Cellular and Molecular Biology

Professor Peter Szlosarek

Professor of Medical Oncology

Dr Bela Wrench

Clinical Senior Lecturer

Key Publications

  • Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 Apr 1;10(4):475-483. doi: 10.1001/jamaoncol.2023.6789. PMID: 38358753 
  • Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia. Sci Transl Med. 2023 Mar;15(685):eabn5135. PMID: 36857430 
  • Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death. Nature Commun (2023) 14(1):2132. PMID: 37059720 
  • PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma. The Journal of Clinical Investigation (2022) 2;132(9):e153436. PMID: 35316216 
  • Reversal of mitochondrial malate dehydrogenase 2 enables anaplerosis via redox rescue in respiration-deficient cells. Molecular Cell (2022) Oct 31;S1097-2765(22)00962-5. PMID: 36327975 
  • MYC sensitises cells to apoptosis by driving energetic demand. Nat Commun (2022) 13(1):4674. PMID: 35945217 
  • Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence. Nat Commun (2021) Sep 17;12(1):5507. PMID: 34535653